ACER GDR REG.S/5 TA 10/ US0044342055 /
| 9/29/2023 8:04:25 AM | Chg. +0.120 | Volume | Bid9:00:08 AM | Ask9:00:08 AM | High | Low |
|---|---|---|---|---|---|---|
| 5.000EUR | +2.46% | 0 Turnover: 0.000 |
4.760Bid Size: 2,720 | 5.150Ask Size: 2,380 | 5.000 | 5.000 |
GlobeNewswire
8/13/2020
Acer Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
GlobeNewswire
7/8/2020
Acer Therapeutics Announces Administration of ACER-001 in a Fasted State Increased Systemic Exposure...
GlobeNewswire
5/14/2020
Acer Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
GlobeNewswire
5/11/2020
Acer Therapeutics to Develop Emetine as Potential COVID-19 Treatment in Collaboration with National ...
GlobeNewswire
4/30/2020
Acer Therapeutics Announces Common Stock Purchase Agreement for up to $15 million with Lincoln Park ...
GlobeNewswire
3/18/2020
Acer Receives Formal Dispute Resolution Request (FDRR) Response from FDA’s Office of New Drugs
GlobeNewswire
3/18/2020
Acer Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate...
GlobeNewswire
2/24/2020
Acer Therapeutics Announces ACER-001 for Urea Cycle Disorders Trial Shows Bioequivalence to BUPHENYL...
GlobeNewswire
12/16/2019
Acer Therapeutics Announces Full Enrollment of Part B in ACER-001 Pivotal Bioavailability and Bioequ...
GlobeNewswire
11/13/2019
Acer Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
GlobeNewswire
10/28/2019
Acer Therapeutics Announces Full Enrollment of Part A in ACER-001 Pivotal Bioavailability and Bioequ...
GlobeNewswire
8/27/2019
Acer Therapeutics to Present at the 21st Annual H.C. Wainwright Global Investment Conference
GlobeNewswire
8/13/2019
Acer Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
GlobeNewswire
7/25/2019
Acer Therapeutics to Host Conference Call and Webcast to Discuss Update on its Pipeline Programs
GlobeNewswire
6/25/2019
Acer Therapeutics Receives Complete Response Letter from U.S. FDA for use of EDSIVO™ (celiprolol) in...
GlobeNewswire
5/31/2019
Acer Therapeutics Announces Poster Presentation at Society for Vascular Medicine Annual Meeting
GlobeNewswire
5/14/2019
Acer Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
GlobeNewswire
4/16/2019
Acer Therapeutics Announces Publication of Vascular Ehlers-Danlos Syndrome (vEDS) Patient Registry D...
GlobeNewswire
3/13/2019
CORRECTING and REPLACING -- Acer Therapeutics to Participate in Upcoming Investor Conferences